Pinaki Biswas

3.8k total citations · 3 hit papers
72 papers, 2.7k citations indexed

About

Pinaki Biswas is a scholar working on Dermatology, Infectious Diseases and Immunology and Allergy. According to data from OpenAlex, Pinaki Biswas has authored 72 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Dermatology, 19 papers in Infectious Diseases and 18 papers in Immunology and Allergy. Recurrent topics in Pinaki Biswas's work include Dermatology and Skin Diseases (24 papers), Allergic Rhinitis and Sensitization (18 papers) and Rheumatoid Arthritis Research and Therapies (12 papers). Pinaki Biswas is often cited by papers focused on Dermatology and Skin Diseases (24 papers), Allergic Rhinitis and Sensitization (18 papers) and Rheumatoid Arthritis Research and Therapies (12 papers). Pinaki Biswas collaborates with scholars based in United States, United Kingdom and Germany. Pinaki Biswas's co-authors include Hernán Valdez, Ricardo Rojo, Eric L. Simpson, Jonathan I. Silverberg, Claire Feeney, Marco DiBonaventura, Jacob P. Thyssen, John D. Kalbfleisch, Thomas Bieber and Seth Forman and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Pinaki Biswas

69 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

2020 313 citations Eric L. Simpson, Michael J. Cork et al. profile →
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

2020 289 citations Jonathan I. Silverberg, Eric L. Simpson et al. profile →
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

2021 287 citations Eric L. Simpson, Jonathan I. Silverberg et al. profile →

Peers

Countries citing papers authored by Pinaki Biswas

Since Specialization

Citations

This map shows the geographic impact of Pinaki Biswas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pinaki Biswas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pinaki Biswas more than expected).

Fields of papers citing papers by Pinaki Biswas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pinaki Biswas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pinaki Biswas. The network helps show where Pinaki Biswas may publish in the future.

Co-authorship network of co-authors of Pinaki Biswas

This figure shows the co-authorship network connecting the top 25 collaborators of Pinaki Biswas. A scholar is included among the top collaborators of Pinaki Biswas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pinaki Biswas. Pinaki Biswas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Isolation and Potential Probiotic Characterization of Lactic Acid Bacteria from an Ethnic Fermented Beverage having Antibacterial Activity against Human Pathogen Entamoeba histolytica 2024 ·International Journal of Pharmaceutical Investigation ·(unknown), Pinaki Biswas, Somasri Dam	1
2	Optimizing maintenance therapy in responders to abrocitinib induction: A post hoc analysis of JADE REGIMEN 2024 ·Journal of the European Academy of Dermatology and Venereology ·Jacob P. Thyssen, Jonathan I. Silverberg, Juan Ruano, Andrew Blauvelt, (unknown), Eric L. Simpson, Stephan Weidinger, Hernán Valdez, Ketti K. Terry, Pinaki Biswas, Eray Metin Güler, Claire Feeney	0
3	50865 Efficacy of Step-up Abrocitinib Treatment in Combination With Topical Medicated Therapy for Treating Atopic Dermatitis Flares: A Post Hoc Analysis of the JADE REGIMEN Trial 2024 ·Journal of the American Academy of Dermatology ·Jonathan I. Silverberg, Eric L. Simpson, Melinda Gooderham, Pinaki Biswas, (unknown), Urs Kerkmann, (unknown)	0
4	P81 Long-term efficacy of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE EXTEND 2023 ·British Journal of Dermatology ·Amy S. Paller, Michael J. Cork, Carsten Flohr, Christine Bangert, Stephan Weidinger, (unknown), (unknown), Pinaki Biswas, (unknown), Herwig Koppensteiner	1
5	Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis and comorbid allergies 2023 ·Allergy ·Peter Schmid‐Grendelmeier, Melinda Gooderham, Karin Hartmann, George Ν. Konstantinou, (unknown), (unknown), Claire Clibborn, Pinaki Biswas, Patrick M. Brunner	2
6	Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study 2023 ·Journal of the European Academy of Dermatology and Venereology ·Kristian Reich, Jonathan I. Silverberg, Kim Papp, Mette Deleuran, Norito Katoh, Bruce Strober, Lisa A. Beck, Marjolein de Bruin‐Weller, Thomas Werfel, Fan Zhang, Pinaki Biswas, Marco DiBonaventura, Gary Chan, Susan Johnson, (unknown), Urs Kerkmann, Claire Clibborn	20
7	Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials 2023 ·SHILAP Revista de lepidopterología ·Melinda Gooderham, Michael R. Ardern‐Jones, Emma Guttman‐Yassky, Mahreen Ameen, Eric L. Simpson, Gary Chan, Pinaki Biswas, (unknown), (unknown)	1
8	Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2 2023 ·American Journal of Clinical Dermatology ·Gil Yosipovitch, Melinda Gooderham, Sonja Ständer, Luz Fonacier, Jacek C. Szepietowski, Mette Deleuran, Giampiero Girolomoni, John Su, Andrew G. Bushmakin, Joseph C. Cappelleri, Claire Feeney, Gary Chan, Andrew Thorpe, Hernán Valdez, Pinaki Biswas, Ricardo Rojo, Marco DiBonaventura, Daniela E. Myers	7
9	Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type 2023 ·Annals of Allergy Asthma & Immunology ·Andrew Alexis, Jonathan I. Silverberg, Zakiya P. Rice, April W. Armstrong, Seemal R. Desai, Luz Fonacier, Kenji Kabashima, Pinaki Biswas, (unknown), Gary Chan, (unknown)	2
10	Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial 2023 ·American Journal of Clinical Dermatology ·Eric L. Simpson, Jonathan I. Silverberg, Jacob P. Thyssen, M. Viguier, Diamant Thaçi, Marjolein de Bruin‐Weller, Stephan Weidinger, (unknown), Marco DiBonaventura, Pinaki Biswas, Claire Feeney, (unknown), Michael J. Cork	14
11	Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis 2023 ·Dermatology ·Jacob P. Thyssen, Anthony Bewley, Sonja Ständer, Carla N. Castro, L. Misery, Brian Kim, Pinaki Biswas, Gary Chan, Daniela E. Myers, (unknown), (unknown), (unknown), Jonathan I. Silverberg	2
12	Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes 2021 ·American Journal of Clinical Dermatology ·Jonathan I. Silverberg, Jacob P. Thyssen, Eric L. Simpson, Gil Yosipovitch, Sonja Ständer, Hernán Valdez, Ricardo Rojo, Pinaki Biswas, Daniela E. Myers, Claire Feeney, Marco DiBonaventura	32
13	Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme 2020 ·RMD Open ·Stanley Cohen, Yoshiya Tanaka, Xavier Mariette, Jeffrey R. Curtis, Eun Bong Lee, Peter Nash, Kevin Winthrop, Christina Charles‐Schoeman, Lisy Wang, Connie Chen, Kenneth Kwok, Pinaki Biswas, Andrea Shapiro, Ann Madsen, J. Wollenhaupt	135
14	An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data 2020 ·Drug Safety ·Gerd R Burmester, Jeffrey R. Curtis, Huifeng Yun, Oliver FitzGerald, Kevin Winthrop, Valderílio Feijó Azevedo, William F. C. Rigby, Keith S. Kanik, Cunshan Wang, Pinaki Biswas, Thomas V. Jones, (unknown), Thijs Hendrikx, Sujatha Menon, Ricardo Rojo	34
15	Molecular characterization of Bu-1 and TLR2 gene in Haringhata Black chicken 2019 ·Genomics ·Aruna Pal, (unknown), Amirul Islam Mallick, Pinaki Biswas, P. N. Chatterjee	6
16	Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program 2018 ·Queensland's institutional digital repository (The University of Queensland) ·Stanley Cohen, Yoshiya Tanaka, Xavier Mariette, Jeffrey R. Curtis, Eun Bong Lee, Peter Nash, Kevin Winthrop, Christina Charles‐Schoeman, Lisy Wang, Connie Chen, Kenneth Kwok, Pinaki Biswas, Andrea Shapiro, Ann Madsen, (unknown)	5
17	The Impact of Linezolid versus Vancomycin on Surgical Interventions for Complicated Skin and Skin Structure Infections Caused by Methicillin-Resistant Staphylococcus aureus 2013 ·Surgical Infections ·Therèse M. Duane, Blair Capitano, Laura Puzniak, Pinaki Biswas, Manjari Joshi	6
18	Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis 2011 ·Critical Care ·Daniel H. Kett, Andrew F. Shorr, Annette C. Reboli, Arlene Reisman, Pinaki Biswas, Haran T. Schlamm	78
19	Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite 2009 ·British Journal of Clinical Pharmacology ·Bharat Damle, Howard D. Uderman, Pinaki Biswas, (unknown), (unknown), Paul Glue	6
20	Treatment of Fibromyalgia with Formula Acupuncture: Investigation of Needle Placement, Needle Stimulation, and Treatment Frequency 2005 ·The Journal of Alternative and Complementary Medicine ·Richard E. Harris, (unknown), David A. Williams, (unknown), Thomas R. Cupps, Frank Petzke, Kimberly H. Groner, Pinaki Biswas, Richard H. Gracely, Daniel J. Clauw	111

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact